Plus Therapeutics Presents Leptomeningeal Metastases Programs at 2024 SNO Annual Meeting in Houston

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, has announced its upcoming presentations at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting scheduled for November 21-24 in Houston, Texas. The company is set to present significant data from its clinical trials and host an educational symposium on the management of leptomeningeal metastases (LM).

One of the key presentations will highlight results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases. This trial is crucial as it provides insights into dose escalation and the selection of the appropriate administered dose for further phases. Dr. Andrew Brenner, an expert in the field, will present this data on November 22, from 7:30 to 9:30 p.m. CST in Hall B3.

Another important presentation will discuss findings from the FORESEE Trial, which investigates the use of circulating tumor cells for better diagnosis and monitoring of LM. Dr. Priya Kumthekar will present on November 24, from 10:15 to 11:45 a.m. CST in Grand Assembly B. This study aims to enhance the understanding of how tumor cells in cerebrospinal fluid can aid in the clinical management of patients with breast cancer and non-small cell lung cancer who develop LM.

A separate presentation, led by Dr. Arushi Tripathy from the University of Michigan Medical School, will delve into the oncogenic changes detected in cerebrospinal fluid tumor cells over time, which could influence treatment strategies for patients with leptomeningeal metastatic disease. This session will take place on November 22, from 7:30 to 9:30 p.m. CST in Hall B3.

The symposium titled “Novel Targeted Radiotherapies to Manage Leptomeningeal Metastases” will be held on November 23, from 12:45 to 1:45 p.m. CST. This event will bring together clinical experts to discuss recent advances and Plus Therapeutics' latest developments in LM therapies. Notable speakers include Dr. Priya Kumthekar, Dr. Jonathan Yang, and Dr. Andrew Brenner.

Leptomeningeal metastases (LM) is a severe complication of cancer, wherein the disease spreads to the cerebrospinal fluid and the membranes surrounding the brain and spinal cord. It is associated with several types of cancer, particularly breast cancer, lung cancer, gastrointestinal cancers, and melanoma. Approximately 3-5% of breast cancer patients may develop LM, and it is generally a terminal condition with low survival rates of 7% at one year and 3% at two years. The incidence of LM is increasing, partly due to extended cancer patient lifespans and the limitations of standard chemotherapies in reaching and treating spinal fluid tumors. Currently, there are no FDA-approved treatments specifically for LM, with patients often facing a poor prognosis.

Rhenium (186Re) obisbemeda is an innovative injectable radiotherapy designed to deliver a high dose of targeted radiation directly to central nervous system tumors. This novel treatment aims to minimize off-target effects and improve outcomes for patients with CNS cancers compared to existing therapies. It leverages the beneficial properties of Rhenium-186, such as its short half-life and potent beta and gamma energies, which enable effective tumor destruction and real-time imaging. This therapy is under evaluation in the ReSPECT-GBM and ReSPECT-LM clinical trials, with support from significant grants and awards, including a $17.6M grant from the Cancer Prevention & Research Institute of Texas.

Plus Therapeutics, Inc. is committed to developing advanced radiotherapeutics to tackle challenging cancers of the central nervous system. With a focus on image-guided local beta radiation and targeted drug delivery, the company is building a promising pipeline of products aimed at improving patient outcomes.